{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:40:50Z","timestamp":1760812850644,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.trim.2021.101373","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T02:48:31Z","timestamp":1613443711000},"page":"101373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Drug delivery formulation impacts cyclosporine efficacy in a humanised mouse model of acute graft versus host disease"],"prefix":"10.1016","volume":"65","author":[{"given":"Jennifer M.","family":"Corbett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Hawthorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan S.","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"English","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2021.101373_bb0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri3212","article-title":"Advances in graft-versus-host disease biology and therapy","volume":"12","author":"Blazar","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trim.2021.101373_bb0010","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/bmt.2014.69","article-title":"Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation","volume":"49","author":"Castilla-Llorente","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2021.101373_bb0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2013.107","article-title":"Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice","volume":"49","author":"Ruutu","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2021.101373_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213913","article-title":"Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation","volume":"14","author":"de Kort","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.trim.2021.101373_bb0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ejh.13233","article-title":"Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation","volume":"103","author":"Stocker","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.trim.2021.101373_bb0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/00007890-198508000-00011","article-title":"Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone","volume":"40","author":"Deeg","year":"1985","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2021.101373_bb0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/03639040601155665","article-title":"Cyclosporine A: a review of current oral and intravenous delivery systems","volume":"33","author":"Beauchesne","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.trim.2021.101373_bb0040","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","article-title":"Cyclosporine","volume":"321","author":"Kahan","year":"1989","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.trim.2021.101373_bb0045","first-page":"965","article-title":"Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt","volume":"6","author":"Guan","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.trim.2021.101373_bb0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.gene.2018.04.043","article-title":"Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: a meta-analysis","volume":"664","author":"Wang","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.trim.2021.101373_bb0055","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.bmt.1702375","article-title":"New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients","volume":"25","author":"Parquet","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2021.101373_bb0060","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/rheumatology\/39.2.156","article-title":"Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group","volume":"39","author":"Yocum","year":"2000","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.trim.2021.101373_bb0065","doi-asserted-by":"crossref","first-page":"396S","DOI":"10.1016\/j.transproceed.2004.01.013","article-title":"Therapeutic drug monitoring of cyclosporine","volume":"36","author":"Jorga","year":"2004","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2021.101373_bb0070","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.bmt.1704960","article-title":"Optimal initial dose of oral cyclosporine in relation to its toxicities for graft-versus-host disease prophylaxis following reduced-intensity stem cell transplantation in Japanese patients","volume":"35","author":"Kishi","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2021.101373_bb0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/03639045.2015.1044905","article-title":"Enhanced colonic delivery of ciclosporin A self-emulsifying drug delivery system encapsulated in coated minispheres","volume":"42","author":"Keohane","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.trim.2021.101373_bb0080","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.V95.9.2754.009k25_2754_2759","article-title":"The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation","volume":"95","author":"Hill","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.trim.2021.101373_bb0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12056","article-title":"Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease","volume":"172","author":"Tobin","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.trim.2021.101373_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1521s81","article-title":"Creation of \u201chumanized\u201d mice to study human immunity","author":"Pearson","year":"2008","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.trim.2021.101373_bb0095","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00007890-199009000-00003","article-title":"The limited efficacy of cyclosporine in preventing rejection and graft-versus-host disease in orthotopic small bowel transplantation in rats","volume":"50","author":"Saat","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2021.101373_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092888","article-title":"Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantation","volume":"9","author":"Satake","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trim.2021.101373_bb0105","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.trim.2021.101373_bb0110","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1083-8791(03)00087-9","article-title":"Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses","volume":"9","author":"Korngold","year":"2003","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.trim.2021.101373_bb0115","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1590\/S0100-879X2006005000145","article-title":"Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease","volume":"40","author":"Nogueira","year":"2007","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.trim.2021.101373_bb0120","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood.V80.12.2964.2964","article-title":"Cytokine dysregulation and acute graft-versus-host disease","volume":"80","author":"Antin","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.trim.2021.101373_bb0125","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood-2008-08-172155","article-title":"IL-17 contributes to CD4-mediated graft-versus-host disease","volume":"113","author":"Kappel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.trim.2021.101373_bb0130","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1053\/j.gastro.2019.01.109","article-title":"P053 targeted release oral cyclosporine formulation as a potential new therapy for ulcerative colitis","volume":"156","author":"Colombel","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trim.2021.101373_bb0135","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1136\/gutjnl-2013-305143.3","article-title":"Colon targeted, low systemic absorption soluble ciclosporin in ulcerative colitis","volume":"62","author":"Donoghue","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.trim.2021.101373_bb0140","doi-asserted-by":"crossref","first-page":"106205","DOI":"10.1016\/j.intimp.2020.106205","article-title":"Berberine combined with cyclosporine A alleviates acute graft-versus-host disease in murine models","volume":"81","author":"Wang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.trim.2021.101373_bb0145","doi-asserted-by":"crossref","first-page":"229s","DOI":"10.1016\/j.transproceed.2004.01.021","article-title":"Cyclosporine nephrotoxicity","volume":"36","author":"Busauschina","year":"2004","journal-title":"Transplant. Proc."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327421000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327421000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:00:03Z","timestamp":1760810403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327421000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":29,"alternative-id":["S0966327421000137"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2021.101373","relation":{},"ISSN":["0966-3274"],"issn-type":[{"type":"print","value":"0966-3274"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug delivery formulation impacts cyclosporine efficacy in a humanised mouse model of acute graft versus host disease","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2021.101373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101373"}}